Cases & Deals

  • Home
  • Practices
  • Puma Biotechnology asserts patent infringement claims under Hatch-Waxman Act related to Nerlynx® against Sandoz

Share

Puma Biotechnology asserts patent infringement claims under Hatch-Waxman Act related to Nerlynx® against Sandoz

November 2021

Client(s) Puma Biotechnology, Inc.

Jones Day is representing Puma Biotechnology, Inc. in a Hatch-Waxman patent infringement action against Sandoz relating to Sandoz's submission of an Abbreviated New Drug Application to the FDA seeking approval of a purported generic version of Nerlynx® (neratinib) tablets.

Puma Biotechnology, Inc., et al. v. Sandoz, Inc., No. 1-21-cv-19918 (D.N.J.)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.